Know Cancer

or
forgot password

Blood Samples to Evaluate Biomarkers of Donor Chimerism


N/A
18 Years
N/A
Not Enrolling
Both
Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome

Thank you

Trial Information

Blood Samples to Evaluate Biomarkers of Donor Chimerism


Inclusion Criteria:



- Diagnosed with a hematologic disease or malignancy

- Scheduled to receive nonablative conditioning with fludarabine and total body
irradiation

- Donor is well-matched by high resolution DNA techniques.

- Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an
oral calcineurin inhibitor.

- Age >18 years at the time of enrollment.

Exclusion criteria:

-Diagnosed with an immunodeficiency disorder

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Donor T-cell chimerism

Outcome Time Frame:

Day 28 post-transplant

Safety Issue:

No

Principal Investigator

Jeannine S McCune, PharmD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Institutional Review Board

Study ID:

FHCRC - 1980.00

NCT ID:

NCT00764829

Start Date:

September 2008

Completion Date:

February 2012

Related Keywords:

  • Leukemia
  • Hodgkins Disease
  • Non-Hodgkins Lymphoma
  • Myelodysplastic Syndrome
  • hematopoietic stem cell transplantation
  • fludarabine
  • mycophenolate mofetil
  • mycophenolic acid
  • biomarkers
  • Hodgkin Disease
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Fred Hutchinson Cancer Research CenterSeattle, Washington  98109